Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis.

Authors

Jonas DE1, Amick HR, Feltner C, Wines R, Shanahan E, Rowe CJ, Garbutt JC

Aim:

To assess whether response to medications for alcohol use disorders varies by genotype.

Material And Methods:

Systematic review and meta-analysis.

Results:

We found no studies that assessed the clinical utility of genotype-guided dosing strategies or genotype-guided medication selection, and none randomized by genotype. All included studies assessed the association between genotype and response to medication. Of 15 included studies, eight (n = 1365 participants) assessed variation in naltrexone response and polymorphisms of OPRM1. Our meta-analyses for return to heavy drinking found no significant difference between A allele homozygotes and those with at least one G allele, both without (risk difference: 0.26; 95% CI: -0.01-0.53; n = 174) and with inclusion of studies rated as high or unclear risk of bias (risk difference: 0.14; 95% CI: -0.03-0.3; n = 382). For all other polymorphism-medication pairs, we found just one eligible study.

Conclusion:

Estimates of effect for return to heavy drinking suggest it is possible that patients with at least one G allele of A118G polymorphism of OPRM1 might be more likely to respond to naltrexone, but confidence intervals were wide; additional studies are needed to improve confidence in the estimates.

Keywords:

OPRM1; alcohol; alcohol dependence; alcohol use disorder; naltrexone; opioid receptor; pharmacogenomics; polymorphism; systematic review

Download Full Research Paper

Interested in Partnering With Us?

Contact us to learn more about incorporating our Naltrexone Recovery Program in your practice or treatment facility.

Learn More
Call Now: 1(888) 711-3143